Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: Too early to take shortcuts?

Journal of Hepatology

Volumn 40, Issue 3, 2004, Pages 536-538

  Mondelli, Mario U ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ANTIGEN; VIRUS NUCLEOPROTEIN;

CLINICAL TRIAL; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTIOUS HEPATITIS; PRIORITY JOURNAL; SEROCONVERSION; VIRUS CORE; VIRUS REPLICATION;

EID: 1242269850     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.01.012     Document Type: Editorial

References (32)

1. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol. 31:1999;54-60.
2. Reed K.E., Rice C.M. Overview of the hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol. 242:2000;55-84.
3. Ray R.B., Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett. 21:2001;149-156.
4. Bouvier-Alias M., Patel K., Dahari H., Beaucourt S., Larderie P., Blatt L., et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 36:2002;211-218.
5. Rebucci C., Cerino A., Cividini A., Timo L., Furione M., Mondelli M.U. Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. J Clin Microbiol. 41:2003;3881-3884.
6. Bertoletti A., Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 38:2003;4-13.
7. Herzer K., Falk C.S., Encke J., Eichhorst S.T., Ulsenheimer A., Seliger B., et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol. 77:2003;8299-8309.
8. Large M.K., Kittlesen D.J., Hahn Y.S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 162:1999;931-938.
9. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest. 106:2000;1239-1249.
10. Bergqvist A., Sundstrom S., Dimberg L.Y., Gylfe E., Masucci M.G. The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations. J Biol Chem. 278:2003;18877-18883.
11. Accapezzato D., Francavilla V., Rawson P., Cerino A., Cividini A., Mondelli M.U., et al. Subversion of CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. Eur J Immunol. 2004;. in press.
12. Tanaka T., Lau J.Y.N., Mizokami M., Orito E., Tanaka E., Kiyosawa K., et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol. 23:1995;742-745.
13. Kashiwakuma T., Hasegawa A., Kajita T., Takata A., Mori H., Ohta Y., et al. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Methods. 190:1996;79-89.
14. Tanaka E., Kiyosawa K., Matsumoto A., Kashiwakuma T., Hasegawa A., Mori H., et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology. 23:1996;1330-1333.
15. Couroucé A.M., Le Marrec N., Bouchardeau F., Razer A., Maniez M., Laperche S., et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion. 40:2000;1198-1202.
16. Icardi G., Ansaldi F., Bruzzone B.M., Durando P., Lee S., de Luigi C., et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol. 39:2001;3110-3114.
17. Widell A., Molnegren V., Pieksma F., Calmann M., Peterson J., Lee S.R. Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase. Transfus Med. 12:2002;107-113.
18. Aoyagi K., Ohue C., Iida K., Kimura T., Tanaka E., Kiyosawa K., et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol. 37:1999;1802-1808.
19. Tanaka E., Ohue C., Aoyagi K., Yamaguchi K., Yagi S., Kiyosawa K., et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology. 32:2000;388-393.
20. Muerhoff A.S., Jiang L., Shah D.O., Gutierrez R.A., Patel J., Garolis C., et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion. 42:2002;349-356.
21. Kurtz J.B., Boxall E., Qusir N., Shirley J., Coleman D., Chandler C. The diagnostic significance of an assay for 'total' hepatitis C core antigen. J Virol Methods. 96:2001;127-132.
22. Cano H., Candela M.J., Lozano M.L., Vicente V. Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfus Med. 13:2003;259-266.
23. Shah D.O., Chang C.D., Jiang L.X., Cheng K.Y., Muerhoff A.S., Gutierrez R.A., et al. Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion. 43:2003;1067-1074.
24. Cividini A., Cerino A., Muzzi A., Furione M., Rebucci C., Segagni L., et al. Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. J Clin Microbiol. 41:2003;2144-2146.
25. Zanetti A.R., Romano L., Brunetto M., Colombo M., Bellati G., Tackney C. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol. 70:2003;27-30.
26. Maynard M., Pradat P., Berthillon P., Picchio G., Voirin N., Martinot M., et al. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J Viral Hepatitis. 10:2003;318-323.
27. Veillon P., Payan C., Picchio G., Maniez-Montreuil M., Guntz P., Lunel F. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol. 41:2003;3212-3220.
28. Lunel F., Veillon P., Fouchard-Hubert I., Loustaud-Ratti V., Abergel A., Silvain C., et al. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J Hepatol. 39:2003;826-833.
29. Buti M., Mendez C., Schaper M., Sauleda S., Valdes A., Rodriguez-Frias F., et al. HCV Core Ag as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin. J Hepatol. 40:2004;527-532.
30. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
31. Alberti A., Benvegnù L. Management of hepatitis C. J Hepatol. 38:2003;S104-S118.
32. Lagging L.M., Garcia C.E., Westin J., Wejstål R., Norkrans G., Dhillon A.P., et al. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol. 40:2002;4224-4229.